Skip to main content

Poolbeg Pharma upbeat on preliminary influenza drug results

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

--News Direct--

Poolbeg Pharma PLC (OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive after announcing initial data analysis, including a 'clear dose-related response', for its drug, POLB 001, a potential treatment for severe influenza. Skillington says the 'early data readout' indicates that the challenge trial was successful.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/poolbeg-pharma-upbeat-on-preliminary-influenza-drug-results-758545326

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  271.58
+36.08 (15.32%)
AAPL  308.91
-24.52 (-7.35%)
AMD  476.15
-9.24 (-1.90%)
BAC  61.95
+0.22 (0.36%)
GOOG  356.65
+22.97 (6.88%)
META  556.71
+17.68 (3.28%)
MSFT  464.72
+13.62 (3.02%)
NVDA  200.75
+5.71 (2.93%)
ORCL  129.87
+2.31 (1.81%)
TSLA  311.21
+2.36 (0.76%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.